Johnson & Johnson (J&J) has signed a collaboration deal with genomics diagnostics company Veracyte Inc. to advance the development of two nasal swab tests for early lung cancer detection.
Under the terms of the agreement, the Lung Cancer Initiative at J&J and Veracyte will combine clinical study cohorts with more than 5,000 patients with multiple years of clinical outcome data, including patients enrolled in a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?